JNJ-26070109

JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease[1].

Product Specifications

CAS Number

[844645-08-5]

UNSPSC

12352005

Target

Cholecystokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/jnj-26070109.html

Concentration

10mM

Purity

99.25

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N[C@@H](C1=CC=C(F)C=C1F)C)C2=CC=C(Br)C=C2NS(=O)(C3=C4N=CC=NC4=CC=C3)=O

Molecular Formula

C23H17BrF2N4O3S

Molecular Weight

547.37

References & Citations

[1]Magda F Morton, et al. JNJ-26070109 [ (R) 4-bromo-N-[1- (2,4-difluoro-phenyl) -ethyl]-2- (quinoxaline-5-sulfonylamino) -benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011 J